MinorEnrollment closed, study ongoingShow 5 more changesShow less
Primary completion moved earlier from Sep 29, 2027 to Aug 25, 2027
Study completion moved earlier from Dec 22, 2027 to Nov 17, 2027
Eligibility criteria expanded, about 22 words
Secondary endpoints: details revised at 1 of 23 entries
Site details revised at 23 of 23 sites
MinorStudy sites: 22 to 23v11
MinorStudy sites: 21 to 22v10
MinorTrial sites expanded: 18 → 21 locationsv9
MinorTrial sites expanded: 15 → 18 locationsv8
Show 2 earlier versionsHide 2 earlier versions
MinorStudy sites: 14 to 15v7
MinorStudy sites: 13 to 14v6
MinorTrial sites expanded: 10 → 13 locationsv5
MinorStudy sites: 9 to 10v4
MinorStudy sites: 7 to 9v3
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 2 to 7
Start date changed from estimate of Mar 9, 2026 to Mar 5, 2026
v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.